Director Sandstrom buys 13,500 shares of JAN at $20.00; holds 21,000 total. Cluster of 5 other insiders buying within 14 days.
Katherine M Sandstrom, a director, purchased 13,500 shares at $20.00, increasing her holdings by 180.0%, from 7,500 to 21,000 shares. This substantial accumulation occurs within a cluster buy pattern where 5 other insiders have also acquired shares within the past 14 days. While the stock is only 3 trading days into its listing and prior 52-week benchmarks are not yet meaningful, the synchronized buying activity across multiple insiders at the same price level ($20.00) suggests shared conviction among the board during the company's early public market phase. The absence of scheduled trading flags indicates this is a discretionary decision by the director.
Director Katherine M Sandstrom purchases 68 TOL shares at $126.87; first buy after extended absence from open-market activity.
Sandstrom made her first open-market purchase, acquiring 68 shares at $126.87, bringing her total holdings from zero to 68 shares. The timing of this buy places the shares $8.84 below the current price of $135.71, and at a price within the 52-week range. Her cross-ticker track record shows only 1 prior buy with an average 90-day return of -0.3% and a win rate of 0.00%, providing limited basis for assessing her trading acumen at this company. TOL itself trades at a P/E of 9.51 with annual revenue growth of +8.5% and has risen 16.1% over the past 90 days, though it remains -19.1% from its 52-week high. The small position size and absence of recent insider activity history limit the strength of the signal, though the purchase does represent a fresh directional commitment to the stock.
Director Katherine M. Sandstrom buys 11,288 shares of DOC at $17.65; 4 other insiders bought within 14 days.
Sandstrom purchased 11,288 shares at $17.65 on 2025-04-28, increasing her holdings by 25.1% to 56,268 shares total. The transaction occurs in the context of a multi-insider cluster, with 4 other insiders also purchasing within the past 14 days. The current price of $17.75 is 23.2% below the 52-week high of $23.12, and the stock has declined 12.1% over 30 days and 14.1% over 90 days. HealthPeak Properties reports a P/E of 44.38 and recent quarterly revenue of $702,889,000.00 with annual growth of 23.8%. The synchronized buying pattern across multiple insiders, combined with the stock trading near its 52-week low, suggests company leadership is accumulating shares during a period of depressed equity pricing.
